Press Releases
Apr 18, 2026
Statement
COVID-19,Corporate and finance,Partnerships
Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study
Mar 30, 2026
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Feb 26, 2026
Corporate and finance
Novavax to Participate in Upcoming Investor Conferences
Feb 26, 2026
Corporate and finance
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Feb 19, 2026
Corporate and finance
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Jan 20, 2026
Press release
Corporate and finance,Partnerships,Science & technology
Novavax Announces Entering into a License Agreement with Pfizer
Jan 7, 2026
Corporate and finance
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Nov 12, 2025
Corporate and finance
Novavax to Participate in Jefferies London Healthcare Conference
Nov 6, 2025
Corporate and finance
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Nov 4, 2025
COVID-19,Corporate and finance
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Showper page